Abdominal vein thrombosis, Splanchnic vein thrombosis Splanchnic vein thrombosis, abdominal vein thrombosis
Conditions
Interventions
None listed
Sponsors
Leids Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Patients with confirmed acute SVT; definitions provided in paragraph 4.2 in the Rhea study protocol (Cases, group 1) - Patients with confirmed non-symptomatic chronic SVT, defined by incident SVT with chronic thrombi on 2 serial imaging tests with at least 3 months interval (controls, group 2) - Aged 18 years and older - Willing and able to give informed consent
Exclusion criteria
Exclusion criteria: - MRI contra-indication (including but not limited to a cardiac pacemaker or subcutaneous defibrillator; vascular clips in the cerebral vessels; metal splinter in the eye, a hearing aid that cannot be removed; a neurostimulator that cannot be removed; a hydrocephalus pump) - A medical condition, associated illness or co-morbid circumstances that precludes completion of the study procedures (MRI and 90-day follow-up assessment), including but not limited to life-expectancy less than 3 months, inability to lie flat, morbid obesity preventing use of MR and claustrophobia. - Patients with decompensated liver disease with Child-Pugh class C cirrhosis (since MRDTI evaluation will be inadequate in these patients) - Patients with suspected tumour thrombus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The sensitivity and specificity of MRDTI for the diagnosis of acute and chronic SVT | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoints are 1) optimized MRDTI scan sequences for SVT; 2) the assessment of interobserver agreement between the reviewers. | — |
Countries
Italy, Netherlands
Contacts
Public ContactF.A Klok
Leids Universitair Medisch Centrum
Outcome results
None listed